Somewhat Positive Media Coverage Somewhat Unlikely to Impact Cyclacel Pharmaceuticals (CYCC) Share Price

News stories about Cyclacel Pharmaceuticals (NASDAQ:CYCC) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cyclacel Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.6043796601447 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Cyclacel Pharmaceuticals (NASDAQ CYCC) traded up $0.02 during trading on Tuesday, hitting $1.76. 125,836 shares of the stock traded hands, compared to its average volume of 144,350. Cyclacel Pharmaceuticals has a one year low of $1.50 and a one year high of $10.90. The firm has a market cap of $20.71, a price-to-earnings ratio of -0.71 and a beta of 3.75.

COPYRIGHT VIOLATION WARNING: This news story was first published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors.

Insider Buying and Selling by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply